# Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Study · id `cardio:ct-nct01849497` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01849497](<https://clinicaltrials.gov/study/NCT01849497>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01849497

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.

## Technical summary

Registry record NCT01849497. Randomized; no masking; primary purpose treatment. Start 2013-04-18 (actual); primary completion 2013-09-02 (actual). Results posted on 2015-10-09.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 149 participants (enrolled count; ClinicalTrials.gov record NCT01849497, source copy `cardio:ctgov-nct01849497-2018-11-29`, retrieved 2026-10-31)
- Started: 2013-04-18 (actual) (ClinicalTrials.gov record NCT01849497, source copy `cardio:ctgov-nct01849497-2018-11-29`, retrieved 2026-10-31)
- Primary completion: 2013-09-02 (actual) (ClinicalTrials.gov record NCT01849497, source copy `cardio:ctgov-nct01849497-2018-11-29`, retrieved 2026-10-31)
- Completion: Not reported
- Results first posted: 2015-10-09 (ClinicalTrials.gov record NCT01849497, source copy `cardio:ctgov-nct01849497-2018-11-29`, retrieved 2026-10-31)
- Countries: United States; Canada (ClinicalTrials.gov record NCT01849497, source copy `cardio:ctgov-nct01849497-2018-11-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01849497-2018-11-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
- Condition: Primary Hypercholesterolemia
- Condition: Mixed Dyslipidemia
- Intervention (Biological): Evolocumab Pre-filled Syringe
- Intervention (Biological): Evolocumab AI/pen
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 9fb086458bfa3ea5fc762f11ff1965edd4ba3481285b82490109dd272bf43431
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
